Ftse Mib
33.949,82
0,60%
DAX
17.953,25
0,17%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.718,92
-0,89%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Crossject (ALCJ) Crossject (ALCJ) Notizie

ALCJ

Crossject (ALCJ)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:ALCJ
DataOraFonteTitoloSimboloCompagnia
30/04/202419:05GlobeNewswire Inc.Crossject annonce le lancement d’une augmentation de capitalEU:ALCJCrossject
25/04/202407:32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
25/04/202407:32GlobeNewswire Inc.Crossject communique ses résultats financiers audités pour 2023EU:ALCJCrossject
10/04/202416:30GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
02/04/202418:35GlobeNewswire Inc.Crossject trading on Euronext to resume as usual on Wednesday April 3EU:ALCJCrossject
02/04/202418:35GlobeNewswire Inc.La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avrilEU:ALCJCrossject
02/04/202410:30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
02/04/202410:30GlobeNewswire Inc.Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023EU:ALCJCrossject
08/03/202407:30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
08/03/202407:30GlobeNewswire Inc.Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024EU:ALCJCrossject
27/02/202408:30GlobeNewswire Inc.Crossject obtains a financing up to €12 million, in two tranchesEU:ALCJCrossject
27/02/202408:30GlobeNewswire Inc.Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranchesEU:ALCJCrossject
06/02/202417:30GlobeNewswire Inc.Crossject publie une mise à jour stratégique de ses priorités pour 2024EU:ALCJCrossject
06/02/202417:30GlobeNewswire Inc.Crossject provides strategic update on priorities for 2024EU:ALCJCrossject
01/02/202418:15GlobeNewswire Inc.Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CETEU:ALCJCrossject
01/02/202418:15GlobeNewswire Inc.Crossject organisera un webcast le 6 février à 17h30 pour faire le point sur sa stratégie commercialeEU:ALCJCrossject
09/01/202416:21GlobeNewswire Inc.Crossject to present at Biotech Showcase on January 9 at 16:30 PTEU:ALCJCrossject
09/01/202416:21GlobeNewswire Inc.Crossject annonce l’initiation de la couverture de son titre par ODDO BHFEU:ALCJCrossject
04/01/202418:00GlobeNewswire Inc.Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-UnisEU:ALCJCrossject
04/01/202418:00GlobeNewswire Inc.Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®EU:ALCJCrossject
22/12/202307:30GlobeNewswire Inc.Crossject signs ZEPIZURE® commercialization agreement for northern EuropeEU:ALCJCrossject
22/12/202307:30GlobeNewswire Inc.Crossject signe un accord de commercialisation pour ZEPIZURE® en Europe du NordEU:ALCJCrossject
28/11/202307:30GlobeNewswire Inc.Crossject announces initiation of coverage by ODDO BHFEU:ALCJCrossject
26/09/202317:35GlobeNewswire Inc.Crossject reports financial results and business highlights for first half of 2023EU:ALCJCrossject
11/09/202307:30GlobeNewswire Inc.Crossject announces significant improvement in Gaïa ESG ratingEU:ALCJCrossject
11/09/202307:30GlobeNewswire Inc.Crossject annonce une nouvelle nette amélioration de sa notation ESG GaïaEU:ALCJCrossject
05/09/202313:00GlobeNewswire Inc.Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizuresEU:ALCJCrossject
05/09/202307:30GlobeNewswire Inc.Crossject annonce avoir passé avec succès des audits européens et américain pour la fabrication de ZENEO® Midazolam dans le traitement des crises d’épilepsieEU:ALCJCrossject
24/07/202318:00GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social février 2023EU:ALCJCrossject
20/07/202316:55GlobeNewswire Inc.Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New ZealandEU:ALCJCrossject
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:ALCJ

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
SPM
Saipem
BIT
AMP
Amplifon
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
A2A
A2A
BIT
LDO
Leonardo
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network